Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Grows By 38.6%

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 37,000 shares, a growth of 38.6% from the November 30th total of 26,700 shares. Based on an average daily volume of 24,300 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.1% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Craig Hallum initiated coverage on SOPHiA GENETICS in a research note on Wednesday, December 18th. They set a "buy" rating and a $11.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $7.40.

SOPHiA GENETICS Price Performance

SOPH traded up $0.17 during trading on Friday, reaching $3.36. The stock had a trading volume of 63,955 shares, compared to its average volume of 62,102. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.59 and a current ratio of 3.80. The business has a 50-day moving average of $3.39 and a 200-day moving average of $3.83. SOPHiA GENETICS has a one year low of $2.70 and a one year high of $7.37. The stock has a market cap of $219.66 million, a PE ratio of -3.08 and a beta of 0.99.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.04). The business had revenue of $15.85 million during the quarter, compared to analysts' expectations of $15.90 million. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. During the same quarter in the previous year, the business earned ($0.21) EPS. As a group, equities research analysts anticipate that SOPHiA GENETICS will post -0.98 EPS for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Principal Financial Group Inc. increased its position in shares of SOPHiA GENETICS by 35.9% in the second quarter. Principal Financial Group Inc. now owns 1,368,378 shares of the company's stock valued at $6,267,000 after acquiring an additional 361,201 shares during the period. Banque Cantonale Vaudoise increased its holdings in SOPHiA GENETICS by 300.0% during the 2nd quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company's stock valued at $55,000 after purchasing an additional 9,000 shares during the period. Federated Hermes Inc. raised its position in SOPHiA GENETICS by 57.5% during the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company's stock valued at $289,000 after purchasing an additional 23,000 shares during the last quarter. Finally, Green Alpha Advisors LLC purchased a new stake in SOPHiA GENETICS in the 3rd quarter worth approximately $79,000. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.